Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Blommestein · SciRah

Researcher profile · Semantic Scholar

H. Blommestein

Share profile

H. Blommestein — researcher profile on SciRah

h-index: 17
Works: 108
Citations: 982

Most-cited papers

Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.
C. V. van Beurden-Tan, M. Franken, H. Blommestein, C. Uyl-de Groot +1 more
2017Journal of Clinical Oncology106 citations
Semantic Scholar
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
G. Sonke, A. van Ommen-Nijhof, N. Wortelboer, V. van der Noort +18 more
2024Nature79 citations Open access
Semantic Scholar
Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).
G. Sonke, A. van Ommen-Nijhof, N. Wortelboer, V. van der Noort +16 more
2023Journal of Clinical Oncology57 citations Open access
Semantic Scholar
Changes in survival in de novo metastatic cancer in an era of new medicines
M. Luyendijk, O. Visser, H. Blommestein, I. D. de Hingh +6 more
2023Journal of the National Cancer Institute45 citations Open access
Semantic Scholar
Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences.
Saskia de Groot, N. van der Linden, M. Franken, H. Blommestein +6 more
2017Value in Health44 citations Open access
Semantic Scholar
The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands.
A. Leunis, H. Blommestein, P. Huijgens, N. M. Blijlevens +2 more
2013Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis41 citations Open access
Semantic Scholar
A cost‐effectiveness analysis of real‐world treatment for elderly patients with multiple myeloma using a full disease model
H. Blommestein, Silvia G. R. Verelst, S. Groot, Peter C. Huijgens +2 more
2016European Journal of Haematology39 citations Open access
Semantic Scholar
A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
H. Blommestein, M. Franken, C. Uyl-de Groot
2015PharmacoEconomics (Auckland)39 citations Open access
Semantic Scholar
Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies
O. Ciani, B. Grigore, H. Blommestein, Saskia de Groot +4 more
2021Medical decision making38 citations Open access
Semantic Scholar
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis
H. Blommestein, C. V. van Beurden-Tan, M. Franken, C. Uyl-de Groot +2 more
2019Haematologica30 citations Open access
Semantic Scholar
Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
N. Büyükkaramikli, H. Blommestein, R. Riemsma, N. Armstrong +6 more
2017PharmacoEconomics (Auckland)30 citations Open access
Semantic Scholar
Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma.
B. Leeneman, M. Franken, V. Coupé, M. Hendriks +7 more
2019European Journal of Surgical Oncology28 citations Open access
Semantic Scholar
Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal
B. Pongiglione, A. Torbica, H. Blommestein, Saskia de Groot +8 more
2021International Journal of Technology Assessment in Health Care25 citations Open access
Semantic Scholar
Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion.
J. Mihajlović, P. Bax, E. van Breugel, H. Blommestein +3 more
2017Clinical Therapeutics24 citations Open access
Semantic Scholar
Long-term Outcomes in Patients With Multiple Myeloma
S. Verelst, H. Blommestein, Saskia de Groot, S. Gonzalez-McQuire +4 more
2018HemaSphere18 citations Open access
Semantic Scholar
Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands.
H. Blommestein, Saskia de Groot, M. Aarts, P. Vemer +4 more
2016Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis17 citations Open access
Semantic Scholar
Cost‐effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population‐based study
H. Blommestein, D. Issa, M. Pompen, G. ten Hoor +5 more
2014European Journal of Haematology17 citations
Semantic Scholar
Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands
Yi-Hsuan Chen, H. Blommestein, R. Klazenga, C. Uyl-de Groot +1 more
2023Cancers16 citations Open access
Semantic Scholar
Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
H. Blommestein, M. Franken, C. V. van Beurden-Tan, N. M. Blijlevens +4 more
2021JAMA Network Open16 citations Open access
Semantic Scholar
A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
M. Seefat, D. Cucchi, Stijn Dirven, K. Groen +2 more
2021Cancers14 citations Open access
Semantic Scholar
Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
S. de Groot, H. Blommestein, W. Redekop, S. Sleijfer +3 more
2017PLoS ONE12 citations Open access
Semantic Scholar
Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country
F. Thielen, M. Houwing, M. Cnossen, Ilona A. al Hadithy-Irgiztseva +4 more
2020Pediatric Blood & Cancer10 citations Open access
Semantic Scholar
Real‐world evidence in health technology assessment of high‐risk medical devices: Fit for purpose?
P. Klein, H. Blommestein, M. Al, B. Pongiglione +2 more
2022Health Economics9 citations Open access
Semantic Scholar
A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands
D. Issa, A. Dinmohamed, M. Wondergem, H. Blommestein +5 more
2020Leukemia and Lymphoma9 citations Open access
Semantic Scholar
Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
M. Franken, J. Gaultney, H. Blommestein, P. Huijgens +3 more
2014Value in Health9 citations
Semantic Scholar
Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
M. Luyendijk, H. Blommestein, C. Uyl-de Groot, S. Siesling +1 more
2023JAMA Network Open8 citations Open access
Semantic Scholar
Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?
E. M. Jongbloed, H. Blommestein, H. V. van Schoubroeck, J. Martens +3 more
2022Breast Cancer8 citations Open access
Semantic Scholar
Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review
Yi-Hsuan Chen, D. Molenaar, C. Uyl-de Groot, M. van Vulpen +1 more
2022Cancers8 citations Open access
Semantic Scholar
Access to expensive cancer drugs in Dutch daily practice: should we be concerned?
H. Blommestein, M. Franken, S. Verelst, M. van Agthoven +2 more
2014Netherlands Journal of Medicine8 citations
Semantic Scholar
Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study
Yi-Hsuan Chen, M. Kroesen, M. Hoogeman, M. Versteegh +2 more
2025Clinical and Translational Radiation Oncology7 citations Open access
Semantic Scholar
Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy
N. Büyükkaramikli, H. Blommestein, R. Riemsma, N. Armstrong +6 more
20177 citations
Semantic Scholar
Estimating Quality of Life Decrements in Oncology Using Time to Death.
M. Versteegh, Ide van der Helm, H. Mokri, S. Oerlemans +2 more
2022Value in Health6 citations Open access
Semantic Scholar
Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial.
M. Seefat, C. Stege, B. I. Lissenberg-Witte, M. Levin +24 more
2024European Journal of Cancer5 citations Open access
Semantic Scholar
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model.
H. Blommestein, Saskia de Groot, B. Leeneman, C. Uyl-de Groot +14 more
2024European Journal of Cancer5 citations Open access
Semantic Scholar
Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
L. Bakker, F. Thielen, W. Redekop, Carin Uyl-de Groot +1 more
2023BMC Medical Research Methodology5 citations Open access
Semantic Scholar
Variation in the utilization of medical devices across Germany, Italy, and the Netherlands: A multilevel approach.
S. Rabbe, Meilin Möllenkamp, B. Pongiglione, H. Blommestein +3 more
2022Health Economics5 citations Open access
Semantic Scholar
Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review.
M. Luyendijk, R. W. M. Vernooij, H. Blommestein, S. Siesling +1 more
2019Value in Health5 citations Open access
Semantic Scholar
Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells: A decision model
F. Thielen, H. Blommestein, L. Oosten, F. Calkoen +9 more
2018European Journal of Haematology5 citations Open access
Semantic Scholar
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.
N. Wortelboer, Seamus Kent, I. Konings, A. van Ommen-Nijhof +16 more
2025European Journal of Cancer4 citations Open access
Semantic Scholar
Changes in income and employment after diagnosis among patients with multiple myeloma in The Netherlands.
Christine Bennink, M. Brink, S. Duijts, Hans Scheurer +2 more
2024Clinical Lymphoma, Myeloma & Leukemia4 citations Open access
Semantic Scholar
Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
M. Luyendijk, A. Jager, S. Buijs, S. Siesling +2 more
2023PharmacoEconomics (Auckland)4 citations Open access
Semantic Scholar
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene
H. Blommestein, N. Armstrong, S. Ryder, S. Deshpande +6 more
2015PharmacoEconomics (Auckland)4 citations Open access
Semantic Scholar
High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study
Christine Bennink, H. Westgeest, Daan Schoonen, Femke Boersen +4 more
2023HemaSphere3 citations Open access
Semantic Scholar
Health‐related quality of life in patients with steroid‐refractory acute graft‐versus‐host disease
B. Leeneman, H. Blommestein, Annemieke van Dongen-Leunis, M. Algeri +4 more
2023European Journal of Haematology3 citations Open access
Semantic Scholar
Treatment sequences and drug costs from diagnosis to death in multiple myeloma
M. R. Seefat, D. G. J. Cucchi, K. Groen, M. Donker +7 more
2023European Journal of Haematology3 citations Open access
Semantic Scholar
Measuring hospital-related burden of treatment in multiple myeloma using Electronic Health Records’-reimbursement data
Christine Bennink, M. van der Klift, P. Sonneveld, J. Hazelzet +1 more
2022Health Policy and Technology3 citations Open access
Semantic Scholar
Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands
B. Leeneman, H. Blommestein, V. Coupé, M. Hendriks +7 more
2021Melanoma research3 citations Open access
Semantic Scholar
The relationship of response on time to next treatment based on evidence from two RCTs in newly diagnosed stem cell transplantation ineligible multiple myeloma patients
C. V. van Beurden-Tan, H. Blommestein, S. Zweegman, P. Sonneveld
20163 citations
Semantic Scholar
Systematic Literature Review and Network Meta-Analysis of Treatments for Relapsed/Refractory Multiple Myeloma Patients
C. V. van Beurden-Tan, M. Franken, H. Blommestein, Carin Uyl-de Groot +1 more
20163 citations
Semantic Scholar
Real-World Evidence on Healthcare Resource use and Associated Cost With Multiple Myeloma in The Netherlands
H. Blommestein, S. Verelst, A. Zagórska, J. Stevanović +5 more
20163 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Uyl-de Groot×28
Invite
C. Uyl-de Groot — researcher profile on SciRah
M. Franken×11
Invite
M. Franken — researcher profile on SciRah
P. Sonneveld×11
Invite
P. Sonneveld — researcher profile on SciRah
Saskia de Groot×7
Invite
Saskia de Groot — researcher profile on SciRah

×6

Invite

P. Huijgens — researcher profile on SciRah

Invite

S. Zweegman — researcher profile on SciRah

C. V. van Beurden-Tan×5

Invite

C. V. van Beurden-Tan — researcher profile on SciRah

Invite

A. Jager — researcher profile on SciRah

Invite

B. Leeneman — researcher profile on SciRah

Invite

A. Beeker — researcher profile on SciRah

M. Luyendijk×4

Invite

M. Luyendijk — researcher profile on SciRah

Invite

S. Siesling — researcher profile on SciRah